{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T07:09:03Z","timestamp":1774422543131,"version":"3.50.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2011,2,23]],"date-time":"2011-02-23T00:00:00Z","timestamp":1298419200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Bone Miner Metab"],"published-print":{"date-parts":[[2011,9]]},"DOI":"10.1007\/s00774-011-0262-z","type":"journal-article","created":{"date-parts":[[2011,2,22]],"date-time":"2011-02-22T09:04:28Z","timestamp":1298365468000},"page":"598-605","source":"Crossref","is-referenced-by-count":18,"title":["Decrease in serum FGF23 levels after intravenous infusion of pamidronate in patients with osteogenesis imperfecta"],"prefix":"10.1007","volume":"29","author":[{"given":"Taichi","family":"Kitaoka","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriyuki","family":"Namba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kohji","family":"Miura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuo","family":"Kubota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhisa","family":"Ohata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Fujiwara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haruhiko","family":"Hirai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takehisa","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiichi","family":"Ozono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,2,23]]},"reference":[{"key":"262_CR1","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/81664","volume":"26","author":"ADHR Consortium","year":"2000","unstructured":"ADHR Consortium (2000) Autosomal dominant hypophosphatemic rickets is associated with mutations in FGF23. Nat Genet 26:345\u2013348","journal-title":"Nat Genet"},{"key":"262_CR2","doi-asserted-by":"crossref","first-page":"6500","DOI":"10.1073\/pnas.101545198","volume":"98","author":"T Shimada","year":"2001","unstructured":"Shimada T, Mizutani S, Muto T, Yoneya T, Hino R, Takeda S, Takeuchi Y, Fujita T, Fukumoto S, Yamashita T (2001) Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci USA 98:6500\u20136505","journal-title":"Proc Natl Acad Sci USA"},{"key":"262_CR3","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1016\/j.bone.2006.12.062","volume":"40","author":"S Fukumoto","year":"2007","unstructured":"Fukumoto S, Yamashita T (2007) FGF23 is a hormone-regulating phosphate metabolism: unique biological characteristics of FGF23. Bone (NY) 40:1190\u20131195","journal-title":"Bone (NY)"},{"key":"262_CR4","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/j.bone.2009.06.017","volume":"45","author":"Y Shimizu","year":"2009","unstructured":"Shimizu Y, Tada Y, Yamauchi M, Okamoto T, Suzuki H, Ito N, Fukumoto S, Sugimoto T, Fujita T (2009) Hypophosphatemia induced by intravenous administration of saccharated ferric oxide: another form of FGF23-related hypophosphatemia. Bone (NY) 45:814\u2013816","journal-title":"Bone (NY)"},{"key":"262_CR5","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.tig.2004.08.007","volume":"20","author":"N Itoh","year":"2004","unstructured":"Itoh N, Ornitz DM (2004) Evolution of the Fgf and Fgfr gene families. Trends Genet 20:563\u2013569","journal-title":"Trends Genet"},{"key":"262_CR6","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1681\/ASN.2007010068","volume":"18","author":"S Liu","year":"2007","unstructured":"Liu S, Quarles LD (2007) How fibroblast growth factor 23 works. J Am Soc Nephrol 18:1637\u20131647","journal-title":"J Am Soc Nephrol"},{"key":"262_CR7","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1097\/01.mnh.0000232885.81142.83","volume":"15","author":"M Kuro-o","year":"2006","unstructured":"Kuro-o M (2006) Klotho as a regulator of fibroblast growth factor signaling and phosphate\/calcium metabolism. Curr Opin Nephrol Hypertens 15:437\u2013441","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"262_CR8","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/j.bone.2004.06.014","volume":"35","author":"M Mirams","year":"2004","unstructured":"Mirams M, Robinson BG, Mason RS, Nelson AE (2004) Bone as a source of FGF23: regulation by phosphate? Bone (NY) 35:1192\u20131199","journal-title":"Bone (NY)"},{"key":"262_CR9","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1016\/j.bone.2007.01.017","volume":"40","author":"Y Yoshiko","year":"2007","unstructured":"Yoshiko Y, Wang H, Minamizaki T, Ijuin C, Yamamoto R, Suemune S, Kozai K, Tanne K, Aubin JE, Maeda N (2007) Mineralized tissue cells are a principal source of FGF23. Bone (NY) 40:1565\u20131573","journal-title":"Bone (NY)"},{"key":"262_CR10","doi-asserted-by":"crossref","first-page":"4957","DOI":"10.1210\/jc.2002-021105","volume":"87","author":"Y Yamazaki","year":"2002","unstructured":"Yamazaki Y, Okazaki R, Shibata M, Hasegawa Y, Satoh K, Tajima T, Takeuchi Y, Fujita T, Nakahara K, Yamashita T, Fukumoto S (2002) Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets\/osteomalacia. J Clin Endocrinol Metab 87:4957\u20134960","journal-title":"J Clin Endocrinol Metab"},{"key":"262_CR11","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1016\/j.bone.2008.02.014","volume":"42","author":"I Endo","year":"2008","unstructured":"Endo I, Fukumoto S, Ozono K, Namba N, Tanaka H, Inoue D, Minagawa M, Sugimoto T, Yamauchi M, Michigami T, Matsumoto T (2008) Clinical usefulness of measurement of fibroblast growth factor 23 (FGF23) in hypophosphatemic patients: proposal of diagnostic criteria using FGF23 measurement. Bone (NY) 42:1235\u20131239","journal-title":"Bone (NY)"},{"key":"262_CR12","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1038\/sj.ki.5002000","volume":"70","author":"Y Nishida","year":"2006","unstructured":"Nishida Y, Taketani Y, Yamanaka-Okumura H, Imamura F, Taniguchi A, Sato T, Shuto E, Nashiki K, Arai H, Yamamoto H, Takeda E (2006) Acute effect of oral phosphate loading on serum fibroblast growth factor 23 levels in healthy men. Kidney Int 70:2141\u20132147","journal-title":"Kidney Int"},{"key":"262_CR13","doi-asserted-by":"crossref","first-page":"5358","DOI":"10.1210\/en.2005-0777","volume":"146","author":"F Perwad","year":"2005","unstructured":"Perwad F, Azam N, Zhang MY, Yamashita T, Tenenhouse HS, Portale AA (2005) Dietary and serum phosphorus regulate fibroblast growth factor 23 expression and 1, 25-dihydroxyvitamin D metabolism in mice. Endocrinology 146:5358\u20135364","journal-title":"Endocrinology"},{"key":"262_CR14","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1359\/jbmr.091109","volume":"25","author":"F Rauch","year":"2010","unstructured":"Rauch F, Lalic L, Roughley P, Glorieux FH (2010) Relationship between genotype and skeletal phenotype in children and adolescents with osteogenesis imperfecta. J Bone Miner Res 25:1367\u20131374","journal-title":"J Bone Miner Res"},{"key":"262_CR15","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1056\/NEJMoa063804","volume":"355","author":"AM Barnes","year":"2006","unstructured":"Barnes AM, Chang W, Morello R, Cabral WA, Weis M, Eyre DR, Leikin S, Makareeva E, Kuznetsova N, Uveges TE, Ashok A, Flor AW, Mulvihill JJ, Wilson PL, Sundaram UT, Lee B, Marini JC (2006) Deficiency of cartilage-associated protein in recessive lethal osteogenesis imperfecta. N Engl J Med 355:2757\u20132764","journal-title":"N Engl J Med"},{"key":"262_CR16","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/ng1968","volume":"39","author":"WA Cabral","year":"2007","unstructured":"Cabral WA, Chang W, Barnes AM, Weis M, Scott MA, Leikin S, Makareeva E, Kuznetsova NV, Rosenbaum KN, Tifft CJ, Bulas DI, Kozma C, Smith PA, Eyre DR, Marini JC (2007) Prolyl 3-hydroxylase 1 deficiency causes a recessive metabolic bone disorder resembling lethal\/severe osteogenesis imperfecta. Nat Genet 39:359\u2013365","journal-title":"Nat Genet"},{"key":"262_CR17","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1056\/NEJMoa0907705","volume":"362","author":"AM Barnes","year":"2010","unstructured":"Barnes AM, Carter EM, Cabral WA, Weis M, Chang W, Makareeva E, Leikin S, Rotimi CN, Eyre DR, Raggio CL, Marini JC (2010) Lack of cyclophilin B in osteogenesis imperfecta with normal collagen folding. N Engl J Med 362:521\u2013528","journal-title":"N Engl J Med"},{"key":"262_CR18","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1136\/jmg.16.2.101","volume":"16","author":"DO Sillence","year":"1979","unstructured":"Sillence DO, Senn AS, Danks DM (1979) Genetic heterogeneity in osteogenesis imperfecta. J Med Genet 16:101\u2013116","journal-title":"J Med Genet"},{"key":"262_CR19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejmg.2009.10.007","volume":"53","author":"FS Dijk Van","year":"2010","unstructured":"Van Dijk FS, Pals G, Van Rijn RR, Nikkels PG, Cobben JM (2010) Classification of osteogenesis imperfecta revisited. Eur J Med Genet 53:1\u20135","journal-title":"Eur J Med Genet"},{"key":"262_CR20","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1172\/JCI0215952","volume":"110","author":"F Rauch","year":"2002","unstructured":"Rauch F, Travers R, Plotkin H, Glorieux FH (2002) The effects of intravenous pamidronate on the bone tissue of children and adolescents with osteogenesis imperfecta. J Clin Invest 110:1293\u20131299","journal-title":"J Clin Invest"},{"key":"262_CR21","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1592\/phco.24.2.195.33143","volume":"24","author":"RE Robinson","year":"2004","unstructured":"Robinson RE, Nahata MC, Hayes JR, Batisky DL, Bates CM, Mahan JD (2004) Effectiveness of pretreatment in decreasing adverse events associated with pamidronate in children and adolescents. Pharmacotherapy 24:195\u2013197","journal-title":"Pharmacotherapy"},{"key":"262_CR22","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.bone.2004.07.003","volume":"35","author":"LA DiMeglio","year":"2004","unstructured":"DiMeglio LA, Ford L, McClintock C, Peacock M (2004) Intravenous pamidronate treatment of children under 36\u00a0months of age with osteogenesis imperfecta. Bone (NY) 35:1038\u20131045","journal-title":"Bone (NY)"},{"key":"262_CR23","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1469-8749.2008.03222.x","volume":"51","author":"H Castillo","year":"2009","unstructured":"Castillo H, Samson-Fang L (2009) American Academy for Cerebral Palsy, Developmental Medicine Treatment Outcomes Committee Review Panel Effects of bisphosphonates in children with osteogenesis imperfecta: an AACPDM systematic review. Dev Med Child Neurol 51:17\u201329","journal-title":"Dev Med Child Neurol"},{"key":"262_CR24","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1210\/jc.2002-021371","volume":"88","author":"F Rauch","year":"2003","unstructured":"Rauch F, Plotkin H, Travers R, Zeitlin L, Glorieux FH (2003) Osteogenesis imperfecta types I, III, and IV: effect of pamidronate therapy on bone and mineral metabolism. J Clin Endocrinol Metab 88:986\u2013992","journal-title":"J Clin Endocrinol Metab"},{"key":"262_CR25","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1210\/jc.85.5.1846","volume":"85","author":"H Plotkin","year":"2000","unstructured":"Plotkin H, Rauch F, Bishop NJ, Montpetit K, Ruck-Gibis J, Travers R, Glorieux FH (2000) Pamidronate treatment of severe osteogenesis imperfecta in children under 3\u00a0years of age. J Clin Endocrinol Metab 85:1846\u20131850","journal-title":"J Clin Endocrinol Metab"},{"key":"262_CR26","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1007\/s00467-010-1565-3","volume":"25","author":"J Silver","year":"2010","unstructured":"Silver J, Navey-Many T (2010) FGF23 and the parathyroid glands. Pediatr Nephrol 25:2241\u20132245","journal-title":"Pediatr Nephrol"},{"key":"262_CR27","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.bone.2007.09.044","volume":"42","author":"K Fuller","year":"2008","unstructured":"Fuller K, Lawrence KM, Ross JL, Grabowska UB, Shiroo M, Samuelsson B, Chambers T (2008) Cathepsin K inhibitors prevent matrix-derived growth factor degradation by human osteoclasts. Bone (NY) 42:200\u2013211","journal-title":"Bone (NY)"},{"key":"262_CR28","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.bone.2006.02.060","volume":"39","author":"LI Plotkin","year":"2006","unstructured":"Plotkin LI, Manolagas SC, Bellido T (2006) Dissociation of the pro-apoptotic effects of bisphosphonates on osteoclasts from their anti-apoptotic effects on osteoblasts\/osteocytes with novel analogs. Bone (NY) 39:443\u2013452","journal-title":"Bone (NY)"},{"key":"262_CR29","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/j.bone.2007.12.225","volume":"42","author":"FP Coxon","year":"2008","unstructured":"Coxon FP, Thompson K, Roelofs AJ, Ebetino FH, Rogers MJ (2008) Visualizing mineral binding and uptake of bisphosphonate by osteoclasts and non-resorbing cells. Bone (NY) 42:848\u2013860","journal-title":"Bone (NY)"},{"key":"262_CR30","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s00774-004-0589-9","volume":"23","author":"T Yamamoto","year":"2005","unstructured":"Yamamoto T, Imanishi Y, Kinoshita E, Nakagomi Y, Shimizu N, Miyauchi A, Satomura K, Koshiyama H, Inaba M, Nishizawa Y, Juppner H, Ozono K (2005) The role of fibroblast growth factor 23 for hypophosphatemia and abnormal regulation of vitamin D metabolism in patients with McCune\u2013Albright syndrome. J Bone Miner Metab 23:231\u2013237","journal-title":"J Bone Miner Metab"}],"container-title":["Journal of Bone and Mineral Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00774-011-0262-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00774-011-0262-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00774-011-0262-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,4]],"date-time":"2024-04-04T11:45:53Z","timestamp":1712231153000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00774-011-0262-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,2,23]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2011,9]]}},"alternative-id":["262"],"URL":"https:\/\/doi.org\/10.1007\/s00774-011-0262-z","relation":{},"ISSN":["0914-8779","1435-5604"],"issn-type":[{"value":"0914-8779","type":"print"},{"value":"1435-5604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,2,23]]}}}